Aree Terapeutiche

IBSA, the 3 generations of hyaluronic acid for infiltrative therapy

IBSA is one of the world leaders in the production of hyaluronic acid by biofermentation. 

Over the years, it has focused its efforts on developing increasingly innovative products in order to best meet the therapeutic needs of physicians and patients in a diversified way: this has led to the birth of three different generations of hyaluronic acid.

The first generation contains single-molecular-weight LINEAR HYALURONIC ACID, which is ultra-pure, biofermentative and not chemically modified and is therefore highly biocompatible. 
In this category, the company has developed products with ever-increasing concentrations, from 0.8% to 2%, a maximum concentration above which it would be difficult to ensure easy extrusion of the product from the syringe during use. 


After several years, IBSA research, in collaboration with the Vanvitelli University of Naples, has developed an innovative technology: NAHYCO® Hybrid Technology which, through controlled heat treatment, makes it possible to obtain hybrid complexes of high and low molecular weight hyaluronic acid and to reach a concentration of 3.2%, ensuring, during injection, the same ease of extrusion from the syringe as with lower concentrations.

IBSA was therefore the first and only company to have developed and marketed HYBRID HYALURONIC ACID formulations that represent the second generation of hyaluronic acid. The presence of hybrid complexes in this new class also improves treatment duration, as there is greater resistance to their degradation. 


Thanks to its long-standing know-how in the production of glycosaminoglycans and the application of NAHYCO® Hybrid Technology, IBSA is now entering a new stage by launching its third generation of Hyaluronic Acid: COMBINED HYBRID HYALURONIC ACID, consisting of hybrid complexes of high molecular weight hyaluronic acid and a new polysaccharide, the sodium chondroitin. The latter is produced by biofermentation through a patented process and, unlike chondroitin sulphate, it is not derived from animal extraction and has rheological properties that make it ideal for use in a medical device. The result is a formulation with one of the highest concentrations of high molecular weight hyaluronic acid on the market (72 mg in 3 mL).

Once again IBSA has given proof of its commitment to Research and Development, with particular attention to the needs of physicians and patients.